The comparison of Memantine and Melatonin on memory

The comparison of memantine and melatonin in alleviation of cognitive impairment after ECT

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N8

Enrollment

Registered

2019-10-02

Start date

2018-08-23

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive disorder. Mental disorder, not otherwise specified

Interventions

Intervention 1: Group 1 Intervention: use of 5 mg per day memantine aboreyhan for 1 month. Intervention 2: Group 2 Intervention: use of 3 mg per day melatonin nature made USA for 1 month.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients undergoing ECT in Baqhiatallah hospital Taking consent form

Exclusion criteria

Exclusion criteria: Patients with history of allergy to melatonin Patients with history of allergy to memantine Addict patients

Design outcomes

Primary

Measure	Time frame
Change in Mimi Mental Status Exam (MMSE) score. Timepoint: 1 month. Method of measurement: questionnaire of Mimi Mental Status Exam (MMSE).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abbasi Nazari

Shahid Beheshti University of Medical Sciences

m_abbasi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026